Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10591992 | Bioorganic & Medicinal Chemistry Letters | 2013 | 6 Pages |
Abstract
Screening of our sample collection led to the identification of a set of benzofurano[3,2-d]pyrimidine-2-one hits acting as nucleotide-competing HIV-1 reverse transcriptase inhibitiors (NcRTI). Significant improvement in antiviral potency was achieved when substituents were introduced at positions N1, C4, C7 and C8 on the benzofuranopyrimidone scaffold. The series was optimized from low micromolar enzymatic activity against HIV-1 RT and no antiviral activity to low nanomolar antiviral potency. Further profiling of inhibitor 30 showed promising overall in vitro properties and also demonstrated that its potency was maintained against viruses resistant to the other major classes of HIV-1 RT inhibitors.
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Martin Tremblay, Richard C. Bethell, Michael G. Cordingley, Patrick DeRoy, Jianmin Duan, Martin Duplessis, Paul J. Edwards, Anne-Marie Faucher, Ted Halmos, Clint A. James, Cyrille Kuhn, Jean-Ãric Lacoste, Louie Lamorte, Steven R. LaPlante,